1. Home
  2. NRIX vs PSNYW Comparison

NRIX vs PSNYW Comparison

Compare NRIX & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • PSNYW
  • Stock Information
  • Founded
  • NRIX 2009
  • PSNYW 2017
  • Country
  • NRIX United States
  • PSNYW Sweden
  • Employees
  • NRIX N/A
  • PSNYW 2547
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • PSNYW Auto Manufacturing
  • Sector
  • NRIX Health Care
  • PSNYW Consumer Discretionary
  • Exchange
  • NRIX Nasdaq
  • PSNYW Nasdaq
  • Market Cap
  • NRIX 728.6M
  • PSNYW 625.2M
  • IPO Year
  • NRIX 2020
  • PSNYW N/A
  • Fundamental
  • Price
  • NRIX $9.91
  • PSNYW $0.34
  • Analyst Decision
  • NRIX Strong Buy
  • PSNYW
  • Analyst Count
  • NRIX 15
  • PSNYW 0
  • Target Price
  • NRIX $29.13
  • PSNYW N/A
  • AVG Volume (30 Days)
  • NRIX 733.8K
  • PSNYW 43.4K
  • Earning Date
  • NRIX 10-10-2025
  • PSNYW 03-06-2025
  • Dividend Yield
  • NRIX N/A
  • PSNYW N/A
  • EPS Growth
  • NRIX N/A
  • PSNYW N/A
  • EPS
  • NRIX N/A
  • PSNYW N/A
  • Revenue
  • NRIX $88,381,000.00
  • PSNYW $2,034,261,000.00
  • Revenue This Year
  • NRIX $74.59
  • PSNYW N/A
  • Revenue Next Year
  • NRIX N/A
  • PSNYW $79.49
  • P/E Ratio
  • NRIX N/A
  • PSNYW N/A
  • Revenue Growth
  • NRIX 41.86
  • PSNYW N/A
  • 52 Week Low
  • NRIX $8.18
  • PSNYW $0.09
  • 52 Week High
  • NRIX $29.56
  • PSNYW $0.61
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 47.82
  • PSNYW 62.69
  • Support Level
  • NRIX $8.97
  • PSNYW $0.25
  • Resistance Level
  • NRIX $9.68
  • PSNYW $0.60
  • Average True Range (ATR)
  • NRIX 0.55
  • PSNYW 0.09
  • MACD
  • NRIX 0.04
  • PSNYW 0.02
  • Stochastic Oscillator
  • NRIX 55.13
  • PSNYW 29.75

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.

Share on Social Networks: